Diagnostic Performance of a Magnetic Resonance Imaging-directed Targeted plus Regional Biopsy Approach in Prostate Cancer Diagnosis: A Systematic Review and Meta-analysis
It has been shown that limiting systematic biopsies to the proximity of magnetic resonance imaging (MRI)-positive prostate lesions is a promising diagnostic biopsy approach. However, considering the high degree of heterogeneity between the studies included in our review, prospective clinical trials...
Saved in:
| Published in | European urology open science (Online) Vol. 40; pp. 95 - 103 |
|---|---|
| Main Authors | , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Netherlands
Elsevier B.V
01.06.2022
Elsevier |
| Subjects | |
| Online Access | Get full text |
| ISSN | 2666-1683 2666-1691 2666-1683 |
| DOI | 10.1016/j.euros.2022.04.001 |
Cover
Loading…
| Abstract | It has been shown that limiting systematic biopsies to the proximity of magnetic resonance imaging (MRI)-positive prostate lesions is a promising diagnostic biopsy approach. However, considering the high degree of heterogeneity between the studies included in our review, prospective clinical trials are needed to further investigate and optimize this MRI-directed targeted plus regional biopsy approach.
Systematic biopsies are additionally recommended to maximize the diagnostic performance of the magnetic resonance imaging (MRI) diagnostic pathway for men with suspected prostate cancer (PCa) and positive scans. To reduce unnecessary systematic biopsies (SBx), MRI-directed approaches comprising targeted plus regional biopsy (TBx + RBx) are being investigated.
To systematically evaluate the diagnostic performance of MRI-directed TBx + RBx approaches in comparison to MRI-directed TBx alone and TBx + SBx approaches.
The MEDLINE and Embase databases were searched according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses process. Identified reports were critically appraised according to the Quality Assessment of Diagnostic Accuracy Studies (QUADAS-2) criteria. Detection of grade group (GG) ≥2 PCa was the endpoint of interest. Fixed-effect meta-analyses were conducted to characterize summary effect sizes and quantify heterogeneity. Only MRI-positive men were included.
A total of eight studies were included for analysis. Among a cumulative total of 2603 men with suspected PCa, the GG ≥2 PCa detection rate did not significantly differ between MRI-directed TBx + RBx and TBx + SBx approaches (risk ratio [RR] 0.95, 95% confidence interval [CI] 0.90–1.01; p = 0.09). The TBx + RBx results were obtained using significantly fewer biopsy cores and avoiding contralateral SBx altogether. By contrast, there was significant difference in GG ≥2 PCa detection between MRI-directed TBx + RBx and TBx approaches (RR 1.18, 95% CI 1.10–1.25; p < 0.001).
MRI-directed TBx + RBx approaches showed a nonsignificant difference in detection of GG ≥2 PCa compared to the recommended practice of MRI-directed TBx + SBx. However, owing to the extensive heterogeneity among the studies included, future prospective clinical studies are needed to further investigate, optimize, and standardize this promising biopsy approach.
We reviewed the scientific literature on prostate biopsy approaches using magnetic resonance imaging (MRI)-directed targeted biopsy plus regional biopsy of the prostate. The studies we identified found arguments to potentially embrace such a combined biopsy approach for future diagnostics in prostate cancer. |
|---|---|
| AbstractList | Systematic biopsies are additionally recommended to maximize the diagnostic performance of the magnetic resonance imaging (MRI) diagnostic pathway for men with suspected prostate cancer (PCa) and positive scans. To reduce unnecessary systematic biopsies (SBx), MRI-directed approaches comprising targeted plus regional biopsy (TBx + RBx) are being investigated.
To systematically evaluate the diagnostic performance of MRI-directed TBx + RBx approaches in comparison to MRI-directed TBx alone and TBx + SBx approaches.
The MEDLINE and Embase databases were searched according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses process. Identified reports were critically appraised according to the Quality Assessment of Diagnostic Accuracy Studies (QUADAS-2) criteria. Detection of grade group (GG) ≥2 PCa was the endpoint of interest. Fixed-effect meta-analyses were conducted to characterize summary effect sizes and quantify heterogeneity. Only MRI-positive men were included.
A total of eight studies were included for analysis. Among a cumulative total of 2603 men with suspected PCa, the GG ≥2 PCa detection rate did not significantly differ between MRI-directed TBx + RBx and TBx + SBx approaches (risk ratio [RR] 0.95, 95% confidence interval [CI] 0.90-1.01;
= 0.09). The TBx + RBx results were obtained using significantly fewer biopsy cores and avoiding contralateral SBx altogether. By contrast, there was significant difference in GG ≥2 PCa detection between MRI-directed TBx + RBx and TBx approaches (RR 1.18, 95% CI 1.10-1.25;
< 0.001).
MRI-directed TBx + RBx approaches showed a nonsignificant difference in detection of GG ≥2 PCa compared to the recommended practice of MRI-directed TBx + SBx. However, owing to the extensive heterogeneity among the studies included, future prospective clinical studies are needed to further investigate, optimize, and standardize this promising biopsy approach.
We reviewed the scientific literature on prostate biopsy approaches using magnetic resonance imaging (MRI)-directed targeted biopsy plus regional biopsy of the prostate. The studies we identified found arguments to potentially embrace such a combined biopsy approach for future diagnostics in prostate cancer. It has been shown that limiting systematic biopsies to the proximity of magnetic resonance imaging (MRI)-positive prostate lesions is a promising diagnostic biopsy approach. However, considering the high degree of heterogeneity between the studies included in our review, prospective clinical trials are needed to further investigate and optimize this MRI-directed targeted plus regional biopsy approach. Systematic biopsies are additionally recommended to maximize the diagnostic performance of the magnetic resonance imaging (MRI) diagnostic pathway for men with suspected prostate cancer (PCa) and positive scans. To reduce unnecessary systematic biopsies (SBx), MRI-directed approaches comprising targeted plus regional biopsy (TBx + RBx) are being investigated. To systematically evaluate the diagnostic performance of MRI-directed TBx + RBx approaches in comparison to MRI-directed TBx alone and TBx + SBx approaches. The MEDLINE and Embase databases were searched according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses process. Identified reports were critically appraised according to the Quality Assessment of Diagnostic Accuracy Studies (QUADAS-2) criteria. Detection of grade group (GG) ≥2 PCa was the endpoint of interest. Fixed-effect meta-analyses were conducted to characterize summary effect sizes and quantify heterogeneity. Only MRI-positive men were included. A total of eight studies were included for analysis. Among a cumulative total of 2603 men with suspected PCa, the GG ≥2 PCa detection rate did not significantly differ between MRI-directed TBx + RBx and TBx + SBx approaches (risk ratio [RR] 0.95, 95% confidence interval [CI] 0.90–1.01; p = 0.09). The TBx + RBx results were obtained using significantly fewer biopsy cores and avoiding contralateral SBx altogether. By contrast, there was significant difference in GG ≥2 PCa detection between MRI-directed TBx + RBx and TBx approaches (RR 1.18, 95% CI 1.10–1.25; p < 0.001). MRI-directed TBx + RBx approaches showed a nonsignificant difference in detection of GG ≥2 PCa compared to the recommended practice of MRI-directed TBx + SBx. However, owing to the extensive heterogeneity among the studies included, future prospective clinical studies are needed to further investigate, optimize, and standardize this promising biopsy approach. We reviewed the scientific literature on prostate biopsy approaches using magnetic resonance imaging (MRI)-directed targeted biopsy plus regional biopsy of the prostate. The studies we identified found arguments to potentially embrace such a combined biopsy approach for future diagnostics in prostate cancer. Context: Systematic biopsies are additionally recommended to maximize the diagnostic performance of the magnetic resonance imaging (MRI) diagnostic pathway for men with suspected prostate cancer (PCa) and positive scans. To reduce unnecessary systematic biopsies (SBx), MRI-directed approaches comprising targeted plus regional biopsy (TBx + RBx) are being investigated. Objective: To systematically evaluate the diagnostic performance of MRI-directed TBx + RBx approaches in comparison to MRI-directed TBx alone and TBx + SBx approaches. Evidence acquisition: The MEDLINE and Embase databases were searched according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses process. Identified reports were critically appraised according to the Quality Assessment of Diagnostic Accuracy Studies (QUADAS-2) criteria. Detection of grade group (GG) ≥2 PCa was the endpoint of interest. Fixed-effect meta-analyses were conducted to characterize summary effect sizes and quantify heterogeneity. Only MRI-positive men were included. Evidence synthesis: A total of eight studies were included for analysis. Among a cumulative total of 2603 men with suspected PCa, the GG ≥2 PCa detection rate did not significantly differ between MRI-directed TBx + RBx and TBx + SBx approaches (risk ratio [RR] 0.95, 95% confidence interval [CI] 0.90–1.01; p = 0.09). The TBx + RBx results were obtained using significantly fewer biopsy cores and avoiding contralateral SBx altogether. By contrast, there was significant difference in GG ≥2 PCa detection between MRI-directed TBx + RBx and TBx approaches (RR 1.18, 95% CI 1.10–1.25; p < 0.001). Conclusions: MRI-directed TBx + RBx approaches showed a nonsignificant difference in detection of GG ≥2 PCa compared to the recommended practice of MRI-directed TBx + SBx. However, owing to the extensive heterogeneity among the studies included, future prospective clinical studies are needed to further investigate, optimize, and standardize this promising biopsy approach. Patient summary: We reviewed the scientific literature on prostate biopsy approaches using magnetic resonance imaging (MRI)-directed targeted biopsy plus regional biopsy of the prostate. The studies we identified found arguments to potentially embrace such a combined biopsy approach for future diagnostics in prostate cancer. Systematic biopsies are additionally recommended to maximize the diagnostic performance of the magnetic resonance imaging (MRI) diagnostic pathway for men with suspected prostate cancer (PCa) and positive scans. To reduce unnecessary systematic biopsies (SBx), MRI-directed approaches comprising targeted plus regional biopsy (TBx + RBx) are being investigated.ContextSystematic biopsies are additionally recommended to maximize the diagnostic performance of the magnetic resonance imaging (MRI) diagnostic pathway for men with suspected prostate cancer (PCa) and positive scans. To reduce unnecessary systematic biopsies (SBx), MRI-directed approaches comprising targeted plus regional biopsy (TBx + RBx) are being investigated.To systematically evaluate the diagnostic performance of MRI-directed TBx + RBx approaches in comparison to MRI-directed TBx alone and TBx + SBx approaches.ObjectiveTo systematically evaluate the diagnostic performance of MRI-directed TBx + RBx approaches in comparison to MRI-directed TBx alone and TBx + SBx approaches.The MEDLINE and Embase databases were searched according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses process. Identified reports were critically appraised according to the Quality Assessment of Diagnostic Accuracy Studies (QUADAS-2) criteria. Detection of grade group (GG) ≥2 PCa was the endpoint of interest. Fixed-effect meta-analyses were conducted to characterize summary effect sizes and quantify heterogeneity. Only MRI-positive men were included.Evidence acquisitionThe MEDLINE and Embase databases were searched according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses process. Identified reports were critically appraised according to the Quality Assessment of Diagnostic Accuracy Studies (QUADAS-2) criteria. Detection of grade group (GG) ≥2 PCa was the endpoint of interest. Fixed-effect meta-analyses were conducted to characterize summary effect sizes and quantify heterogeneity. Only MRI-positive men were included.A total of eight studies were included for analysis. Among a cumulative total of 2603 men with suspected PCa, the GG ≥2 PCa detection rate did not significantly differ between MRI-directed TBx + RBx and TBx + SBx approaches (risk ratio [RR] 0.95, 95% confidence interval [CI] 0.90-1.01; p = 0.09). The TBx + RBx results were obtained using significantly fewer biopsy cores and avoiding contralateral SBx altogether. By contrast, there was significant difference in GG ≥2 PCa detection between MRI-directed TBx + RBx and TBx approaches (RR 1.18, 95% CI 1.10-1.25; p < 0.001).Evidence synthesisA total of eight studies were included for analysis. Among a cumulative total of 2603 men with suspected PCa, the GG ≥2 PCa detection rate did not significantly differ between MRI-directed TBx + RBx and TBx + SBx approaches (risk ratio [RR] 0.95, 95% confidence interval [CI] 0.90-1.01; p = 0.09). The TBx + RBx results were obtained using significantly fewer biopsy cores and avoiding contralateral SBx altogether. By contrast, there was significant difference in GG ≥2 PCa detection between MRI-directed TBx + RBx and TBx approaches (RR 1.18, 95% CI 1.10-1.25; p < 0.001).MRI-directed TBx + RBx approaches showed a nonsignificant difference in detection of GG ≥2 PCa compared to the recommended practice of MRI-directed TBx + SBx. However, owing to the extensive heterogeneity among the studies included, future prospective clinical studies are needed to further investigate, optimize, and standardize this promising biopsy approach.ConclusionsMRI-directed TBx + RBx approaches showed a nonsignificant difference in detection of GG ≥2 PCa compared to the recommended practice of MRI-directed TBx + SBx. However, owing to the extensive heterogeneity among the studies included, future prospective clinical studies are needed to further investigate, optimize, and standardize this promising biopsy approach.We reviewed the scientific literature on prostate biopsy approaches using magnetic resonance imaging (MRI)-directed targeted biopsy plus regional biopsy of the prostate. The studies we identified found arguments to potentially embrace such a combined biopsy approach for future diagnostics in prostate cancer.Patient summaryWe reviewed the scientific literature on prostate biopsy approaches using magnetic resonance imaging (MRI)-directed targeted biopsy plus regional biopsy of the prostate. The studies we identified found arguments to potentially embrace such a combined biopsy approach for future diagnostics in prostate cancer. It has been shown that limiting systematic biopsies to the proximity of magnetic resonance imaging (MRI)-positive prostate lesions is a promising diagnostic biopsy approach. However, considering the high degree of heterogeneity between the studies included in our review, prospective clinical trials are needed to further investigate and optimize this MRI-directed targeted plus regional biopsy approach. Take Home MessageIt has been shown that limiting systematic biopsies to the proximity of magnetic resonance imaging (MRI)-positive prostate lesions is a promising diagnostic biopsy approach. However, considering the high degree of heterogeneity between the studies included in our review, prospective clinical trials are needed to further investigate and optimize this MRI-directed targeted plus regional biopsy approach. |
| Author | Padhani, Anwar R. Fernandez Salamanca, Mar Hagens, Marinus J. van der Poel, Henk G. van Leeuwen, Pim J. Schoots, Ivo G. |
| Author_xml | – sequence: 1 givenname: Marinus J. orcidid: 0000-0001-6699-0201 surname: Hagens fullname: Hagens, Marinus J. email: m.hagens2@amsterdamumc.nl organization: Department of Urology, Amsterdam University Medical Centers VUmc, Amsterdam, The Netherlands – sequence: 2 givenname: Mar surname: Fernandez Salamanca fullname: Fernandez Salamanca, Mar organization: Department of Radiology, Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands – sequence: 3 givenname: Anwar R. surname: Padhani fullname: Padhani, Anwar R. organization: Paul Strickland Scanner Centre, Mount Vernon Cancer Centre, Northwood, UK – sequence: 4 givenname: Pim J. surname: van Leeuwen fullname: van Leeuwen, Pim J. organization: Department of Urology, Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands – sequence: 5 givenname: Henk G. surname: van der Poel fullname: van der Poel, Henk G. organization: Department of Urology, Amsterdam University Medical Centers VUmc, Amsterdam, The Netherlands – sequence: 6 givenname: Ivo G. surname: Schoots fullname: Schoots, Ivo G. organization: Department of Radiology, Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/35540708$$D View this record in MEDLINE/PubMed |
| BookMark | eNqFUl1v0zAUjdAQG2O_AAn5kZcW27GTGsSkMr4qbWJi49m6dW4ylzQudjrUv8Sv5GYt0zYJ7cmW7_m48jnPs70udJhlLwUfCy6KN4sxrmNIY8mlHHM15lw8yQ5kURQjUUzyvTv3_ewopQXnXGohilI-y_ZzrRUv-eQg-_PRQ9OF1HvHzjHWIS6hc8hCzYCd0QiHyXdMobt5ny2h8V0zqnxE12PFLiE2OFxW7ToRsPGEbNkHH1Zpw6arVQzgrpjv2Dnt20OP7GRQimzn7NNbNmUXm9TjErZm1x5_M-gqdoY9jID0NgR7kT2toU14tDsPsx-fP12efB2dfvsyO5mejlyRy34EAEaUXItS5JpOLYxGJ12lwRjJFf3DvFKoxbyuJ1KBqXnFpVPcyYnjfJ4fZrOtbhVgYVfRLyFubABvbx5CbCxEWrRFC1xJrZ2pTD1XBsXE6cpxUIU0VakMkNbxVmu1ni-xctj1Edp7ovcnnb-yTbi2hpdGFIIEXu8EYvi1xtTbpU8O2xY6DOtkKWWpVZnniqCv7nrdmvwLmwD5FuAoiRSxvoUIbodW2YW9aZUdWmW5stQqYpkHLOcpRoqZFvbtI9z3Wy5SXpRqtMl5pPS39aEP9Y_wjx_wXes776D9iRtMi7COVI5khU3EsRdD54fKS0l1L4ucBN79X-BR-7_yfxTB |
| CitedBy_id | crossref_primary_10_1016_j_euros_2022_07_006 crossref_primary_10_1016_j_eururo_2024_07_001 crossref_primary_10_1038_s41391_024_00884_2 crossref_primary_10_1016_j_rcl_2023_06_011 crossref_primary_10_1007_s00345_024_04947_w crossref_primary_10_1186_s13244_024_01680_1 crossref_primary_10_1016_j_eclinm_2025_103164 crossref_primary_10_1016_j_euo_2022_08_005 crossref_primary_10_1016_j_euo_2024_10_006 crossref_primary_10_1016_j_eururo_2024_03_027 crossref_primary_10_1016_j_euros_2022_08_005 crossref_primary_10_1016_j_ejrad_2023_110763 crossref_primary_10_1007_s00120_023_02063_y crossref_primary_10_1186_s12885_024_13391_3 crossref_primary_10_37699_2308_7005_6_2024_12 crossref_primary_10_1007_s13629_023_00391_4 crossref_primary_10_1016_j_fjurol_2024_102572 crossref_primary_10_2214_AJR_24_31991 crossref_primary_10_1016_j_euros_2024_03_006 crossref_primary_10_3390_diagnostics13152608 crossref_primary_10_1016_j_clgc_2024_102121 crossref_primary_10_3390_cancers15194800 crossref_primary_10_1111_bju_16579 crossref_primary_10_1007_s00330_022_09097_4 crossref_primary_10_1007_s41973_024_00255_3 crossref_primary_10_1007_s00345_022_04185_y crossref_primary_10_3390_curroncol31070308 crossref_primary_10_1016_j_euo_2023_12_002 crossref_primary_10_1016_j_urolonc_2024_11_023 crossref_primary_10_1016_j_mednuc_2023_07_006 crossref_primary_10_1007_s00345_022_04230_w crossref_primary_10_1016_j_euros_2025_01_006 crossref_primary_10_1002_pros_24585 crossref_primary_10_1186_s12894_024_01461_4 |
| Cites_doi | 10.1097/01.ju.0000070928.49986.04 10.1111/bju.12750 10.1016/j.euo.2019.10.001 10.1056/NEJMoa1801993 10.1097/01.ju.0000112763.74119.d4 10.1097/PAS.0000000000001497 10.1371/journal.pmed.1002813 10.1016/j.urolonc.2018.10.009 10.1016/j.juro.2017.08.040 10.1016/j.urolonc.2022.01.011 10.1097/JU.0000000000001832 10.1016/j.eururo.2019.02.033 10.1016/j.crad.2019.08.020 10.7326/0003-4819-138-1-200301070-00012-w1 10.1016/j.urolonc.2016.11.006 10.4081/aiua.2016.4.292 10.1001/jamanetworkopen.2018.0219 10.1016/j.eururo.2020.04.016 10.1007/s00345-015-1650-0 10.1016/j.eururo.2013.03.030 10.1016/j.eururo.2018.11.023 10.1016/j.eururo.2020.05.038 10.1111/bju.14974 10.1186/1471-2288-3-25 10.1007/s00261-020-02667-4 10.1016/j.eururo.2021.01.039 10.1016/j.eururo.2019.04.008 10.1371/journal.pmed.1000097 10.1097/JU.0000000000002182 10.1016/S1470-2045(18)30569-2 10.1016/j.ejrad.2021.109587 10.1016/j.euf.2020.06.020 10.11152/mu-1705 10.1016/j.eururo.2021.10.032 10.1016/j.urolonc.2021.02.027 10.1111/bju.14865 10.1097/JU.0000000000001406 10.1016/j.urology.2016.11.017 |
| ContentType | Journal Article |
| Copyright | 2022 The Author(s) The Author(s) 2022 The Author(s). 2022 The Author(s) 2022 |
| Copyright_xml | – notice: 2022 The Author(s) – notice: The Author(s) – notice: 2022 The Author(s). – notice: 2022 The Author(s) 2022 |
| DBID | 6I. AAFTH AAYXX CITATION NPM 7X8 5PM DOA |
| DOI | 10.1016/j.euros.2022.04.001 |
| DatabaseName | ScienceDirect Open Access Titles Elsevier:ScienceDirect:Open Access CrossRef PubMed MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef PubMed MEDLINE - Academic |
| DatabaseTitleList | PubMed MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 2666-1683 |
| EndPage | 103 |
| ExternalDocumentID | oai_doaj_org_article_a04255c9d9fb49e18c5dc0a4629d749a PMC9079161 35540708 10_1016_j_euros_2022_04_001 S2666168322000763 1_s2_0_S2666168322000763 |
| Genre | Journal Article Review |
| GroupedDBID | .1- .FO 0R~ 1P~ 53G AAEDW AALRI AAXUO AAYWO ACLIJ ACVFH ADCNI ADVLN AEUPX AFJKZ AFPUW AFRHN AIGII AITUG AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ APXCP EBS FDB GROUPED_DOAJ M41 M~E OK1 ROL RPM Z5R AFCTW AIKHN NCXOZ 6I. AAFTH AAYXX CITATION NPM 7X8 5PM |
| ID | FETCH-LOGICAL-c632t-aaa91705171357055195ec2cd5a99204002bd4e51bff824a9f0d02c40c28c00b3 |
| IEDL.DBID | DOA |
| ISSN | 2666-1683 2666-1691 |
| IngestDate | Wed Aug 27 01:32:14 EDT 2025 Thu Aug 21 14:12:01 EDT 2025 Fri Jul 11 00:55:12 EDT 2025 Thu Jan 02 22:38:16 EST 2025 Tue Jul 01 02:27:45 EDT 2025 Thu Apr 24 23:02:20 EDT 2025 Sun Apr 06 06:54:11 EDT 2025 Tue Feb 25 20:03:19 EST 2025 Tue Aug 26 19:33:08 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Keywords | Systematic biopsies Regional biopsies Prostate biopsy Prostate cancer Diagnostic accuracy |
| Language | English |
| License | This is an open access article under the CC BY license. 2022 The Author(s). This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c632t-aaa91705171357055195ec2cd5a99204002bd4e51bff824a9f0d02c40c28c00b3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-Review-3 content type line 23 |
| ORCID | 0000-0001-6699-0201 |
| OpenAccessLink | https://doaj.org/article/a04255c9d9fb49e18c5dc0a4629d749a |
| PMID | 35540708 |
| PQID | 2662547334 |
| PQPubID | 23479 |
| PageCount | 9 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_a04255c9d9fb49e18c5dc0a4629d749a pubmedcentral_primary_oai_pubmedcentral_nih_gov_9079161 proquest_miscellaneous_2662547334 pubmed_primary_35540708 crossref_primary_10_1016_j_euros_2022_04_001 crossref_citationtrail_10_1016_j_euros_2022_04_001 elsevier_sciencedirect_doi_10_1016_j_euros_2022_04_001 elsevier_clinicalkeyesjournals_1_s2_0_S2666168322000763 elsevier_clinicalkey_doi_10_1016_j_euros_2022_04_001 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2022-06-01 |
| PublicationDateYYYYMMDD | 2022-06-01 |
| PublicationDate_xml | – month: 06 year: 2022 text: 2022-06-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | Netherlands |
| PublicationPlace_xml | – name: Netherlands |
| PublicationTitle | European urology open science (Online) |
| PublicationTitleAlternate | Eur Urol Open Sci |
| PublicationYear | 2022 |
| Publisher | Elsevier B.V Elsevier |
| Publisher_xml | – name: Elsevier B.V – name: Elsevier |
| References | Le Nobin, Orczyk, Deng (b0150) 2014; 114 Rouvière, Puech, Renard-Penna (b0120) 2019; 20 Singh, Canto, Shariat (b0165) 2004; 171 Kasivisvanathan, Rannikko, Borghi (b0110) 2018; 378 Turkbey, Rosenkrantz, Haider (b0075) 2019; 76 Feuer, Meng, Rosenkrantz (b0145) 2021; 205 Park, Park, Lim (b0065) 2020; 45 Franklin, Gianduzzo, Yaxley (b0155) 2020; 126 Costa, Kay, Pedrosa (b0160) 2017; 35 Bossuyt, Reitsma, Bruns (b0100) 2003; 138 Andras, Crisan, Cata (b0010) 2019; 21 Mottet, van den Bergh, Briers (b0005) 2021 Moher, Liberati, Tetzlaff (b0070) 2009; 6 Noguchi, Stamey, McNeal, Nolley (b0030) 2003; 170 Papagiannopoulos, Abern, Wilson (b0040) 2018; 199 Diamand R, Hollans M, Lefebvre Y, et al. The role of perilesional and multiparametric resonance imaging-targeted biopsies to reduce the risk of upgrading at radical prostatectomy pathology: a retrospective monocentric study. Urol Oncol. In press. Lahoud, Doan, Kim, Patel (b0190) 2021; 80 Barrett, Patterson, Koo (b0015) 2016; 34 Padhani, Villeirs, Ahmed (b0185) 2020; 78 Lee, Yang, Lee (b0025) 2021; 39 van Leenders, van der Kwast, Grignon (b0180) 2020; 44 Hansen, Barrett, Lloyd (b0090) 2020; 125 Ahdoot, Williams, Daneshvar (b0115) 2022; 207 Latifoltojar, Appayya, Barrett (b0080) 2019; 74 Klingebiel, Arsov, Ullrich (b0140) 2021; 137 Bryk, Llukani, Taneja (b0045) 2017; 102 Schoots, Padhani, Rouvière, Barentsz, Richenberg (b0035) 2020; 3 Vickers, Carlsson, Cooperberg (b0170) 2020; 78 . Galosi, Maselli, Sbrollini (b0200) 2016; 88 Immerzeel, Israël, Bomers (b0020) 2022; 81 Tschirdewahn, Wiesenfarth, Bonekamp (b0095) 2021; 7 Moore, Kasivisvanathan, Eggener (b0105) 2013; 64 Raman, Sarma, Raman (b0060) 2021; 206 Lu, Syed, Ghabili (b0195) 2019; 76 Freifeld, Xi, Passoni, Woldu (b0050) 2019; 37 Whiting, Rutjes, Reitsma (b0085) 2003; 3 Jambor, Verho, Ettala (b0130) 2019; 16 Drost, Osses, Nieboer (b0135) 2019; 2019 Boesen, Nørgaard, Løgager (b0125) 2018; 1 van der Leest, Cornel, Israël (b0055) 2019; 75 van der Leest (10.1016/j.euros.2022.04.001_b0055) 2019; 75 Latifoltojar (10.1016/j.euros.2022.04.001_b0080) 2019; 74 Boesen (10.1016/j.euros.2022.04.001_b0125) 2018; 1 Barrett (10.1016/j.euros.2022.04.001_b0015) 2016; 34 Tschirdewahn (10.1016/j.euros.2022.04.001_b0095) 2021; 7 Ahdoot (10.1016/j.euros.2022.04.001_b0115) 2022; 207 Singh (10.1016/j.euros.2022.04.001_b0165) 2004; 171 Galosi (10.1016/j.euros.2022.04.001_b0200) 2016; 88 Park (10.1016/j.euros.2022.04.001_b0065) 2020; 45 Mottet (10.1016/j.euros.2022.04.001_b0005) 2021 Andras (10.1016/j.euros.2022.04.001_b0010) 2019; 21 Feuer (10.1016/j.euros.2022.04.001_b0145) 2021; 205 Lu (10.1016/j.euros.2022.04.001_b0195) 2019; 76 Padhani (10.1016/j.euros.2022.04.001_b0185) 2020; 78 Lahoud (10.1016/j.euros.2022.04.001_b0190) 2021; 80 Whiting (10.1016/j.euros.2022.04.001_b0085) 2003; 3 Hansen (10.1016/j.euros.2022.04.001_b0090) 2020; 125 Vickers (10.1016/j.euros.2022.04.001_b0170) 2020; 78 van Leenders (10.1016/j.euros.2022.04.001_b0180) 2020; 44 Lee (10.1016/j.euros.2022.04.001_b0025) 2021; 39 Bossuyt (10.1016/j.euros.2022.04.001_b0100) 2003; 138 Noguchi (10.1016/j.euros.2022.04.001_b0030) 2003; 170 Le Nobin (10.1016/j.euros.2022.04.001_b0150) 2014; 114 Immerzeel (10.1016/j.euros.2022.04.001_b0020) 2022; 81 Freifeld (10.1016/j.euros.2022.04.001_b0050) 2019; 37 Rouvière (10.1016/j.euros.2022.04.001_b0120) 2019; 20 Schoots (10.1016/j.euros.2022.04.001_b0035) 2020; 3 Jambor (10.1016/j.euros.2022.04.001_b0130) 2019; 16 Raman (10.1016/j.euros.2022.04.001_b0060) 2021; 206 Papagiannopoulos (10.1016/j.euros.2022.04.001_b0040) 2018; 199 Turkbey (10.1016/j.euros.2022.04.001_b0075) 2019; 76 Klingebiel (10.1016/j.euros.2022.04.001_b0140) 2021; 137 Costa (10.1016/j.euros.2022.04.001_b0160) 2017; 35 10.1016/j.euros.2022.04.001_b0175 Kasivisvanathan (10.1016/j.euros.2022.04.001_b0110) 2018; 378 Bryk (10.1016/j.euros.2022.04.001_b0045) 2017; 102 Moher (10.1016/j.euros.2022.04.001_b0070) 2009; 6 Drost (10.1016/j.euros.2022.04.001_b0135) 2019; 2019 Franklin (10.1016/j.euros.2022.04.001_b0155) 2020; 126 Moore (10.1016/j.euros.2022.04.001_b0105) 2013; 64 |
| References_xml | – volume: 34 start-page: 501 year: 2016 end-page: 508 ident: b0015 article-title: Targeted transperineal biopsy of the prostate has limited additional benefit over background cores for larger MRI-identified tumors publication-title: World J Urol – volume: 39 start-page: 782.e15 year: 2021 end-page: 782.e21 ident: b0025 article-title: Limitations of overlapping cores in systematic and MRI-US fusion biopsy publication-title: Urol Oncol – volume: 64 start-page: 544 year: 2013 end-page: 552 ident: b0105 article-title: Standards of reporting for MRI-targeted biopsy studies (START) of the prostate: recommendations from an international working group publication-title: Eur Urol – volume: 1 start-page: e180219 year: 2018 ident: b0125 article-title: Assessment of the diagnostic accuracy of biparametric magnetic resonance imaging for prostate cancer in biopsy-naive men: the Biparametric MRI for Detection of Prostate Cancer (BIDOC) study publication-title: JAMA Netw Open – volume: 21 start-page: 37 year: 2019 end-page: 44 ident: b0010 article-title: MRI-TRUS fusion guided prostate biopsy – initial experience and assessment of the role of contralateral lobe systematic biopsy publication-title: Med Ultrason – volume: 2019 start-page: CD012663 year: 2019 ident: b0135 article-title: Prostate MRI, with or without MRI-targeted biopsy, and systematic biopsy for detecting prostate cancer publication-title: Cochrane Database Syst Rev – volume: 76 start-page: 340 year: 2019 end-page: 351 ident: b0075 article-title: Prostate Imaging Reporting and Data System version 2.1: 2019 update of Prostate Imaging Reporting and Data System version 2 publication-title: Eur Urol – volume: 137 start-page: 109587 year: 2021 ident: b0140 article-title: Reasons for missing clinically significant prostate cancer by targeted magnetic resonance imaging/ultrasound fusion–guided biopsy publication-title: Eur J Radiol – year: 2021 ident: b0005 article-title: EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer – volume: 37 start-page: 57 year: 2019 end-page: 62 ident: b0050 article-title: Optimal sampling scheme in men with abnormal multiparametric MRI undergoing MRI-TRUS fusion prostate biopsy publication-title: Urol Oncol – volume: 3 start-page: 32 year: 2020 end-page: 41 ident: b0035 article-title: Analysis of magnetic resonance imaging-directed biopsy strategies for changing the paradigm of prostate cancer diagnosis publication-title: Eur Urol Oncol – volume: 78 start-page: 307 year: 2020 end-page: 309 ident: b0185 article-title: Platinum opinion counterview: the evidence base for the benefit of magnetic resonance imaging–directed prostate cancer diagnosis is sound publication-title: Eur Urol – volume: 138 start-page: W1 year: 2003 end-page: W12 ident: b0100 article-title: The STARD statement for reporting studies of diagnostic accuracy: explanation and elaboration publication-title: Ann Intern Med – volume: 20 start-page: 100 year: 2019 end-page: 109 ident: b0120 article-title: Diagnostic added value of prostate systematic and targeted biopsy based on multiparametric MRI in biopsy-naïve patients: the MRI-FIRST study publication-title: Lancet Oncol – volume: 80 start-page: 260 year: 2021 end-page: 261 ident: b0190 article-title: Perilesional biopsies increase detection of significant prostate cancer in men with PI-RADS 4/5 lesions: validation of the PI-RADS Steering Committee recommendation publication-title: Eur Urol – volume: 207 start-page: 95 year: 2022 end-page: 107 ident: b0115 article-title: Why does MRI-targeted biopsy miss clinically significant cancer? publication-title: J Urol – volume: 6 start-page: e1000097 year: 2009 ident: b0070 article-title: Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement publication-title: PLoS Med – volume: 171 start-page: 1089 year: 2004 end-page: 1092 ident: b0165 article-title: Improved detection of clinically significant, curable prostate cancer with systematic 12-core biopsy publication-title: J Urol – volume: 206 start-page: 595 year: 2021 end-page: 603 ident: b0060 article-title: Optimizing spatial biopsy sampling for the detection of prostate cancer publication-title: J Urol – volume: 125 start-page: 260 year: 2020 end-page: 269 ident: b0090 article-title: Optimising the number of cores for magnetic resonance imaging–guided targeted and systematic transperineal prostate biopsy publication-title: BJU Int – volume: 7 start-page: 1300 year: 2021 end-page: 1307 ident: b0095 article-title: Detection of significant prostate cancer using target saturation in transperineal magnetic resonance imaging/transrectal ultrasonography–fusion biopsy publication-title: Eur Urol Focus – reference: Diamand R, Hollans M, Lefebvre Y, et al. The role of perilesional and multiparametric resonance imaging-targeted biopsies to reduce the risk of upgrading at radical prostatectomy pathology: a retrospective monocentric study. Urol Oncol. In press. – volume: 74 start-page: 895.e1 year: 2019 end-page: 895.e15 ident: b0080 article-title: Similarities and differences between Likert and PIRADS v2.1 scores of prostate multiparametric MRI: a pictorial review of histology-validated cases publication-title: Clin Radiol – volume: 114 start-page: E105 year: 2014 end-page: E112 ident: b0150 article-title: Prostate tumour volumes: evaluation of the agreement between magnetic resonance imaging and histology using novel co-registration software publication-title: BJU Int – volume: 16 start-page: e1002813 year: 2019 ident: b0130 article-title: Validation of IMPROD biparametric MRI in men with clinically suspected prostate cancer: a prospective multi-institutional trial publication-title: PLoS Med – volume: 44 start-page: e87 year: 2020 end-page: e99 ident: b0180 article-title: The 2019 International Society of Urological Pathology (ISUP) consensus conference on grading of prostatic carcinoma publication-title: Am J Surg Pathol – reference: . – volume: 88 start-page: 292 year: 2016 end-page: 295 ident: b0200 article-title: Cognitive zonal fusion biopsy of the prostate: original technique between target and saturation publication-title: Arch Ital Urol Androl – volume: 45 start-page: 4166 year: 2020 end-page: 4177 ident: b0065 article-title: Comparison of biopsy strategies for prostate biopsy according to lesion size and PSA density in MRI-directed biopsy pathway publication-title: Abdom Radiol – volume: 76 start-page: 14 year: 2019 end-page: 17 ident: b0195 article-title: Role of core number and location in targeted magnetic resonance imaging-ultrasound fusion prostate biopsy publication-title: Eur Urol – volume: 75 start-page: 570 year: 2019 end-page: 578 ident: b0055 article-title: Head-to-head comparison of transrectal ultrasound-guided prostate biopsy versus multiparametric prostate resonance imaging with subsequent magnetic resonance-guided biopsy in biopsy-naïve men with elevated prostate-specific antigen: a large prospective multicenter clinical study publication-title: Eur Urol – volume: 35 start-page: 149.e15 year: 2017 end-page: 149.e21 ident: b0160 article-title: An initial negative round of targeted biopsies in men with highly suspicious multiparametric magnetic resonance findings does not exclude clinically significant prostate cancer—preliminary experience publication-title: Urol Oncol – volume: 102 start-page: 178 year: 2017 end-page: 182 ident: b0045 article-title: The role of ipsilateral and contralateral transrectal ultrasound-guided systematic prostate biopsy in men with unilateral magnetic resonance imaging lesion undergoing magnetic resonance imaging-ultrasound fusion-targeted prostate biopsy publication-title: Urology – volume: 205 start-page: 740 year: 2021 end-page: 747 ident: b0145 article-title: Application of the PRECISION trial biopsy strategy to a contemporary magnetic resonance imaging–targeted biopsy cohort—how many clinically significant prostate cancers are missed? publication-title: J Urol – volume: 126 start-page: 6 year: 2020 end-page: 11 ident: b0155 article-title: Use of a trizonal schema to assess targeting accuracy in prostatic fusion biopsy publication-title: BJU Int – volume: 199 start-page: 155 year: 2018 end-page: 160 ident: b0040 article-title: Predictors of infectious complications after targeted prophylaxis for prostate needle biopsy publication-title: J Urol – volume: 3 start-page: 25 year: 2003 ident: b0085 article-title: The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews publication-title: BMC Med Res Methodol – volume: 170 start-page: 459 year: 2003 end-page: 463 ident: b0030 article-title: Prognostic factors for multifocal prostate cancer in radical prostatectomy specimens: lack of significance of secondary cancers publication-title: J Urol – volume: 378 start-page: 1767 year: 2018 end-page: 1777 ident: b0110 article-title: MRI-targeted or standard biopsy for prostate-cancer diagnosis publication-title: N Engl J Med – volume: 78 start-page: 304 year: 2020 end-page: 306 ident: b0170 article-title: Routine use of magnetic resonance imaging for early detection of prostate cancer is not justified by the clinical trial evidence publication-title: Eur Urol – volume: 81 start-page: 110 year: 2022 end-page: 117 ident: b0020 article-title: Multiparametric magnetic resonance imaging for the detection of clinically significant prostate cancer: what urologists need to know. Part 4: transperineal magnetic resonance-ultrasound fusion guided biopsy using local anesthesia publication-title: Eur Urol – volume: 170 start-page: 459 year: 2003 ident: 10.1016/j.euros.2022.04.001_b0030 article-title: Prognostic factors for multifocal prostate cancer in radical prostatectomy specimens: lack of significance of secondary cancers publication-title: J Urol doi: 10.1097/01.ju.0000070928.49986.04 – volume: 114 start-page: E105 year: 2014 ident: 10.1016/j.euros.2022.04.001_b0150 article-title: Prostate tumour volumes: evaluation of the agreement between magnetic resonance imaging and histology using novel co-registration software publication-title: BJU Int doi: 10.1111/bju.12750 – volume: 3 start-page: 32 year: 2020 ident: 10.1016/j.euros.2022.04.001_b0035 article-title: Analysis of magnetic resonance imaging-directed biopsy strategies for changing the paradigm of prostate cancer diagnosis publication-title: Eur Urol Oncol doi: 10.1016/j.euo.2019.10.001 – volume: 378 start-page: 1767 year: 2018 ident: 10.1016/j.euros.2022.04.001_b0110 article-title: MRI-targeted or standard biopsy for prostate-cancer diagnosis publication-title: N Engl J Med doi: 10.1056/NEJMoa1801993 – volume: 171 start-page: 1089 year: 2004 ident: 10.1016/j.euros.2022.04.001_b0165 article-title: Improved detection of clinically significant, curable prostate cancer with systematic 12-core biopsy publication-title: J Urol doi: 10.1097/01.ju.0000112763.74119.d4 – volume: 44 start-page: e87 year: 2020 ident: 10.1016/j.euros.2022.04.001_b0180 article-title: The 2019 International Society of Urological Pathology (ISUP) consensus conference on grading of prostatic carcinoma publication-title: Am J Surg Pathol doi: 10.1097/PAS.0000000000001497 – volume: 16 start-page: e1002813 year: 2019 ident: 10.1016/j.euros.2022.04.001_b0130 article-title: Validation of IMPROD biparametric MRI in men with clinically suspected prostate cancer: a prospective multi-institutional trial publication-title: PLoS Med doi: 10.1371/journal.pmed.1002813 – volume: 37 start-page: 57 year: 2019 ident: 10.1016/j.euros.2022.04.001_b0050 article-title: Optimal sampling scheme in men with abnormal multiparametric MRI undergoing MRI-TRUS fusion prostate biopsy publication-title: Urol Oncol doi: 10.1016/j.urolonc.2018.10.009 – volume: 2019 start-page: CD012663 year: 2019 ident: 10.1016/j.euros.2022.04.001_b0135 article-title: Prostate MRI, with or without MRI-targeted biopsy, and systematic biopsy for detecting prostate cancer publication-title: Cochrane Database Syst Rev – volume: 199 start-page: 155 year: 2018 ident: 10.1016/j.euros.2022.04.001_b0040 article-title: Predictors of infectious complications after targeted prophylaxis for prostate needle biopsy publication-title: J Urol doi: 10.1016/j.juro.2017.08.040 – ident: 10.1016/j.euros.2022.04.001_b0175 doi: 10.1016/j.urolonc.2022.01.011 – volume: 206 start-page: 595 year: 2021 ident: 10.1016/j.euros.2022.04.001_b0060 article-title: Optimizing spatial biopsy sampling for the detection of prostate cancer publication-title: J Urol doi: 10.1097/JU.0000000000001832 – volume: 76 start-page: 340 year: 2019 ident: 10.1016/j.euros.2022.04.001_b0075 article-title: Prostate Imaging Reporting and Data System version 2.1: 2019 update of Prostate Imaging Reporting and Data System version 2 publication-title: Eur Urol doi: 10.1016/j.eururo.2019.02.033 – volume: 74 start-page: 895.e1 year: 2019 ident: 10.1016/j.euros.2022.04.001_b0080 article-title: Similarities and differences between Likert and PIRADS v2.1 scores of prostate multiparametric MRI: a pictorial review of histology-validated cases publication-title: Clin Radiol doi: 10.1016/j.crad.2019.08.020 – volume: 138 start-page: W1 year: 2003 ident: 10.1016/j.euros.2022.04.001_b0100 article-title: The STARD statement for reporting studies of diagnostic accuracy: explanation and elaboration publication-title: Ann Intern Med doi: 10.7326/0003-4819-138-1-200301070-00012-w1 – volume: 35 start-page: 149.e15 year: 2017 ident: 10.1016/j.euros.2022.04.001_b0160 article-title: An initial negative round of targeted biopsies in men with highly suspicious multiparametric magnetic resonance findings does not exclude clinically significant prostate cancer—preliminary experience publication-title: Urol Oncol doi: 10.1016/j.urolonc.2016.11.006 – volume: 88 start-page: 292 year: 2016 ident: 10.1016/j.euros.2022.04.001_b0200 article-title: Cognitive zonal fusion biopsy of the prostate: original technique between target and saturation publication-title: Arch Ital Urol Androl doi: 10.4081/aiua.2016.4.292 – volume: 1 start-page: e180219 year: 2018 ident: 10.1016/j.euros.2022.04.001_b0125 article-title: Assessment of the diagnostic accuracy of biparametric magnetic resonance imaging for prostate cancer in biopsy-naive men: the Biparametric MRI for Detection of Prostate Cancer (BIDOC) study publication-title: JAMA Netw Open doi: 10.1001/jamanetworkopen.2018.0219 – volume: 78 start-page: 304 year: 2020 ident: 10.1016/j.euros.2022.04.001_b0170 article-title: Routine use of magnetic resonance imaging for early detection of prostate cancer is not justified by the clinical trial evidence publication-title: Eur Urol doi: 10.1016/j.eururo.2020.04.016 – volume: 34 start-page: 501 year: 2016 ident: 10.1016/j.euros.2022.04.001_b0015 article-title: Targeted transperineal biopsy of the prostate has limited additional benefit over background cores for larger MRI-identified tumors publication-title: World J Urol doi: 10.1007/s00345-015-1650-0 – volume: 64 start-page: 544 year: 2013 ident: 10.1016/j.euros.2022.04.001_b0105 article-title: Standards of reporting for MRI-targeted biopsy studies (START) of the prostate: recommendations from an international working group publication-title: Eur Urol doi: 10.1016/j.eururo.2013.03.030 – volume: 75 start-page: 570 year: 2019 ident: 10.1016/j.euros.2022.04.001_b0055 publication-title: Eur Urol doi: 10.1016/j.eururo.2018.11.023 – volume: 78 start-page: 307 year: 2020 ident: 10.1016/j.euros.2022.04.001_b0185 article-title: Platinum opinion counterview: the evidence base for the benefit of magnetic resonance imaging–directed prostate cancer diagnosis is sound publication-title: Eur Urol doi: 10.1016/j.eururo.2020.05.038 – volume: 126 start-page: 6 issue: Suppl 1 year: 2020 ident: 10.1016/j.euros.2022.04.001_b0155 article-title: Use of a trizonal schema to assess targeting accuracy in prostatic fusion biopsy publication-title: BJU Int doi: 10.1111/bju.14974 – volume: 3 start-page: 25 year: 2003 ident: 10.1016/j.euros.2022.04.001_b0085 article-title: The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews publication-title: BMC Med Res Methodol doi: 10.1186/1471-2288-3-25 – volume: 45 start-page: 4166 year: 2020 ident: 10.1016/j.euros.2022.04.001_b0065 article-title: Comparison of biopsy strategies for prostate biopsy according to lesion size and PSA density in MRI-directed biopsy pathway publication-title: Abdom Radiol doi: 10.1007/s00261-020-02667-4 – volume: 80 start-page: 260 year: 2021 ident: 10.1016/j.euros.2022.04.001_b0190 article-title: Perilesional biopsies increase detection of significant prostate cancer in men with PI-RADS 4/5 lesions: validation of the PI-RADS Steering Committee recommendation publication-title: Eur Urol doi: 10.1016/j.eururo.2021.01.039 – volume: 76 start-page: 14 year: 2019 ident: 10.1016/j.euros.2022.04.001_b0195 article-title: Role of core number and location in targeted magnetic resonance imaging-ultrasound fusion prostate biopsy publication-title: Eur Urol doi: 10.1016/j.eururo.2019.04.008 – volume: 6 start-page: e1000097 year: 2009 ident: 10.1016/j.euros.2022.04.001_b0070 article-title: Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement publication-title: PLoS Med doi: 10.1371/journal.pmed.1000097 – volume: 207 start-page: 95 year: 2022 ident: 10.1016/j.euros.2022.04.001_b0115 article-title: Why does MRI-targeted biopsy miss clinically significant cancer? publication-title: J Urol doi: 10.1097/JU.0000000000002182 – volume: 20 start-page: 100 year: 2019 ident: 10.1016/j.euros.2022.04.001_b0120 article-title: Diagnostic added value of prostate systematic and targeted biopsy based on multiparametric MRI in biopsy-naïve patients: the MRI-FIRST study publication-title: Lancet Oncol doi: 10.1016/S1470-2045(18)30569-2 – volume: 137 start-page: 109587 year: 2021 ident: 10.1016/j.euros.2022.04.001_b0140 article-title: Reasons for missing clinically significant prostate cancer by targeted magnetic resonance imaging/ultrasound fusion–guided biopsy publication-title: Eur J Radiol doi: 10.1016/j.ejrad.2021.109587 – volume: 7 start-page: 1300 year: 2021 ident: 10.1016/j.euros.2022.04.001_b0095 article-title: Detection of significant prostate cancer using target saturation in transperineal magnetic resonance imaging/transrectal ultrasonography–fusion biopsy publication-title: Eur Urol Focus doi: 10.1016/j.euf.2020.06.020 – volume: 21 start-page: 37 year: 2019 ident: 10.1016/j.euros.2022.04.001_b0010 article-title: MRI-TRUS fusion guided prostate biopsy – initial experience and assessment of the role of contralateral lobe systematic biopsy publication-title: Med Ultrason doi: 10.11152/mu-1705 – volume: 81 start-page: 110 year: 2022 ident: 10.1016/j.euros.2022.04.001_b0020 article-title: Multiparametric magnetic resonance imaging for the detection of clinically significant prostate cancer: what urologists need to know. Part 4: transperineal magnetic resonance-ultrasound fusion guided biopsy using local anesthesia publication-title: Eur Urol doi: 10.1016/j.eururo.2021.10.032 – volume: 39 start-page: 782.e15 year: 2021 ident: 10.1016/j.euros.2022.04.001_b0025 article-title: Limitations of overlapping cores in systematic and MRI-US fusion biopsy publication-title: Urol Oncol doi: 10.1016/j.urolonc.2021.02.027 – year: 2021 ident: 10.1016/j.euros.2022.04.001_b0005 – volume: 125 start-page: 260 year: 2020 ident: 10.1016/j.euros.2022.04.001_b0090 article-title: Optimising the number of cores for magnetic resonance imaging–guided targeted and systematic transperineal prostate biopsy publication-title: BJU Int doi: 10.1111/bju.14865 – volume: 205 start-page: 740 year: 2021 ident: 10.1016/j.euros.2022.04.001_b0145 article-title: Application of the PRECISION trial biopsy strategy to a contemporary magnetic resonance imaging–targeted biopsy cohort—how many clinically significant prostate cancers are missed? publication-title: J Urol doi: 10.1097/JU.0000000000001406 – volume: 102 start-page: 178 year: 2017 ident: 10.1016/j.euros.2022.04.001_b0045 article-title: The role of ipsilateral and contralateral transrectal ultrasound-guided systematic prostate biopsy in men with unilateral magnetic resonance imaging lesion undergoing magnetic resonance imaging-ultrasound fusion-targeted prostate biopsy publication-title: Urology doi: 10.1016/j.urology.2016.11.017 |
| SSID | ssj0002511672 |
| Score | 2.3764677 |
| SecondaryResourceType | review_article |
| Snippet | It has been shown that limiting systematic biopsies to the proximity of magnetic resonance imaging (MRI)-positive prostate lesions is a promising diagnostic... Take Home MessageIt has been shown that limiting systematic biopsies to the proximity of magnetic resonance imaging (MRI)-positive prostate lesions is a... Systematic biopsies are additionally recommended to maximize the diagnostic performance of the magnetic resonance imaging (MRI) diagnostic pathway for men with... Context: Systematic biopsies are additionally recommended to maximize the diagnostic performance of the magnetic resonance imaging (MRI) diagnostic pathway for... |
| SourceID | doaj pubmedcentral proquest pubmed crossref elsevier |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 95 |
| SubjectTerms | Diagnostic accuracy Prostate biopsy Prostate cancer Regional biopsies Review – Prostate Cancer Systematic biopsies Urology |
| Title | Diagnostic Performance of a Magnetic Resonance Imaging-directed Targeted plus Regional Biopsy Approach in Prostate Cancer Diagnosis: A Systematic Review and Meta-analysis |
| URI | https://www.clinicalkey.com/#!/content/1-s2.0-S2666168322000763 https://www.clinicalkey.es/playcontent/1-s2.0-S2666168322000763 https://dx.doi.org/10.1016/j.euros.2022.04.001 https://www.ncbi.nlm.nih.gov/pubmed/35540708 https://www.proquest.com/docview/2662547334 https://pubmed.ncbi.nlm.nih.gov/PMC9079161 https://doaj.org/article/a04255c9d9fb49e18c5dc0a4629d749a |
| Volume | 40 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELZQD4gL4s3yqIzEkYjYcR7mti1UBWlRpbZSb9b4EQgq2VWze-Av8Svx2E7YBdReuK1iO954Ps2M7ZlvCHmdcyiZRepL0FUmatCZrjjLrLENkrsAY5iNvPhcHZ-LTxflxVapL4wJi_TAceHeAqKqNNLKVgvpWGNKa3IQFZe2FjK4Rt7mbW2mUAej41yFyk3eAFUZq5pipBwKwV2BK9LvDjkPRKepJMxolgJ7_451-tv7_DOIcssqHd0jd5M7SefxM-6TW65_QG4v0oX5Q_LzfQyl88305HeOAF22FOjCN2EOI8Uz_D48__g9VC3KoqVzlp6FSHH_Y3W5GXzHL-HokB50y9Xwg84TIzntenqC-SPec6WH-KYrmmbuhnd0Tk8nwmgabyMo9JYu3BoySLQoj8j50Yezw-MslWfITFXwdQYAEsl4GFb5Q1IeJktnuLElSMlROXBthSuZbtuGC5BtbnNuRG54Y_JcF4_JXr_s3VNCtdSy5GUrGvTPoAG_yQSogUvtUNwzwkfpKJO4y7GExqUag9S-qSBShSJVucBQvRl5Mw1aReqO67sfoNinrsi7HR54NKqERnUTGmdEjKBRY2qrV8b-Rd31c9f_GuaGpFAGxdTgO6tThDOimfNwiVrMSDWNTD5TRMjNU74aMa28RsFrIujdcuM7VX5PLOqiEDPyJGJ8WhT0Tr2RaPwf3kH_zqrttvTd18BaLvPab0XYs_-xzM_JHfyUGLL3guytrzbupXcO13o_6IH9cGr3C-vPY9Y |
| linkProvider | Directory of Open Access Journals |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Diagnostic+Performance+of+a+Magnetic+Resonance+Imaging-directed+Targeted+plus+Regional+Biopsy+Approach+in+Prostate+Cancer+Diagnosis%3A+A+Systematic+Review+and+Meta-analysis&rft.jtitle=European+urology+open+science+%28Online%29&rft.au=Hagens%2C+Marinus+J.&rft.au=Fernandez+Salamanca%2C+Mar&rft.au=Padhani%2C+Anwar+R.&rft.au=van+Leeuwen%2C+Pim+J.&rft.date=2022-06-01&rft.pub=Elsevier+B.V&rft.issn=2666-1683&rft.eissn=2666-1683&rft.volume=40&rft.spage=95&rft.epage=103&rft_id=info:doi/10.1016%2Fj.euros.2022.04.001&rft.externalDocID=S2666168322000763 |
| thumbnail_m | http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F26661683%2FS2666168322X00062%2Fcov150h.gif |